Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q1 2022 Earnings Presentation
11 slides from Phibro Animal Health's earnings presentation, Nov 3, 2021
Slide 1: Phibro Animal Health Corporation Webcast and Conference Call
Phibro Animal Health Corporation Webcast and Conference Call November 3, 2021 Financial Results U.S. toll-free +1-888-330-2022 Fiscal Year 2022 International toll +1-365-977-0051 First Quarter Ended September 30, 2021 Conference ID: 3927884
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current
Slide 3: Key Themes
Key Themes First Quarter Performance in Return on Supply chain and COVID-19 Revised financial line, encouraged strategic labor challenges variants remain guidance by sales growth investments persist a risk We are most Vaccine growth Increased costs We are raising full Vaccine and encouraged by inclu
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated First Quarter, Year-on-Year comparison $ in millions, except per share data Net Sales – $19.5 million, or 10%, increase driven by improvements across all three business segments: Animal YOY Health, Mineral Nutrition and Performance Products. Q1 %∆ Net Income
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health First Quarter, Year-on-Year comparison $ in millions Net Sales YOY MFAs and other Q1 %∆ - Increased $5.1 million, or 6%, driven by stronger international demand, primarily for poultry and cattle products in the Latin America and Southeast Asia Animal Health
Slide 6: Financial Performance – Animal Health reconciliation
Financial Performance – Animal Health First Quarter, Year-on-Year reconciliation $ in millions Adjusted Net Adjusted EBITDA The $12.6 million of incremental sales drove resulted in $5.3 Animal Health Sales EBITDA Margin million of adjusted EBITDA; $2.7 million and $2.6 million attributable to volu
Slide 7: Financial Performance – Other Segments
Financial Performance – Other Segments First Quarter, Year-on-Year comparison $ in millions YOY Q1 %∆ Mineral Nutrition Mineral Nutrition - Net Sales increased $3.0 million, or 6%, driven by increased Net Sales $ 54.4 6% average selling prices, partially offset by lower volumes Adj. EBITDA $ 4.5 4
Slide 8: Key Capitalization Metrics
Key Capitalization Metrics First Quarter Highlights $21.1 million of trailing 12-month free cash flow; operating Free Cash Flow1 cash flow $50.4 million less capital expenditures of $29.3 million 3.8x gross leverage ratio; $406 million total debt / Leverage $106 million trailing 12-month adjusted EB
Slide 9: Revised Financial Guidance
Revised Financial Guidance Fiscal Year 2022 $ in millions, except per share data FY 2022 Guidance The potential economic impact of Previous Revised COVID-19 variants remain a risk. FY21 Q1 FY22 Low High Low High We are raising the range of net sales Consolidated financial guidance by $20 million
Slide 10: Q&A
Phibro 10 November 3, 2021 HEALTHY ANIMALS, HEALTHY FOOD. HEALTHY WORLD. * uc net CORPORAT CN
Slide 11: Trademark notice
© 2021 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy Animals. Healthy Food. Healthy World.; and any other Phibro brand or brands shown herein are trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates. Any other trademark that